| Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial A Lamarca, DH Palmer, HS Wasan, PJ Ross, YT Ma, A Arora, S Falk, ... The Lancet Oncology 22 (5), 690-701, 2021 | 514 | 2021 |
| ABC-06| A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+ mFOLFOX) for patients (pts … A Lamarca, DH Palmer, HS Wasan, PJ Ross, YT Ma, A Arora, S Falk, ... Journal of Clinical Oncology 37 (15_suppl), 4003-4003, 2019 | 272 | 2019 |
| The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays N Tewari, AM Zaitoun, A Arora, S Madhusudan, M Ilyas, DN Lobo BMC cancer 13, 1-10, 2013 | 91 | 2013 |
| Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer TMA Abdel-Fatah, FK Middleton, A Arora, D Agarwal, T Chen, ... Molecular oncology 9 (3), 569-585, 2015 | 90 | 2015 |
| Human helicase RECQL4 drives cisplatin resistance in gastric cancer by activating an AKT–YB1–MDR1 signaling pathway D Mo, H Fang, K Niu, J Liu, M Wu, S Li, T Zhu, MA Aleskandarany, A Arora, ... Cancer Research 76 (10), 3057-3066, 2016 | 89 | 2016 |
| Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy N Albarakati, TMA Abdel-Fatah, R Doherty, R Russell, D Agarwal, ... Molecular oncology 9 (1), 204-217, 2015 | 85 | 2015 |
| ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers TMA Abdel-Fatah, A Arora, P Moseley, C Coveney, C Perry, K Johnson, ... BBA clinical 2, 10-17, 2014 | 66 | 2014 |
| Transcriptomic and protein expression analysis reveals clinicopathological significance of bloom syndrome helicase (BLM) in breast cancer A Arora, TMA Abdel-Fatah, D Agarwal, R Doherty, PM Moseley, ... Molecular cancer therapeutics 14 (4), 1057-1065, 2015 | 53 | 2015 |
| Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts TMA Abdel-Fatah, A Arora, N Alsubhi, D Agarwal, PM Moseley, C Perry, ... Neoplasia 16 (11), 982-991, 2014 | 50 | 2014 |
| 5-Carboxylcytosine levels are elevated in human breast cancers and gliomas M Eleftheriou, AJ Pascual, LM Wheldon, C Perry, A Abakir, A Arora, ... Clinical epigenetics 7, 1-6, 2015 | 48 | 2015 |
| RECQL4 helicase has oncogenic potential in sporadic breast cancers A Arora, D Agarwal, TMA Abdel‐Fatah, H Lu, DL Croteau, P Moseley, ... The Journal of pathology 238 (4), 495-501, 2016 | 47 | 2016 |
| Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer RA Shamanna, H Lu, DL Croteau, A Arora, D Agarwal, G Ball, ... Oncotarget 7 (12), 13269, 2016 | 45 | 2016 |
| Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer N Alsubhi, F Middleton, TMA Abdel-Fatah, P Stephens, R Doherty, ... Molecular Oncology 10 (2), 213-223, 2016 | 38 | 2016 |
| Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers A Arora, TMA Abdel-Fatah, D Agarwal, R Doherty, DL Croteau, ... Carcinogenesis 37 (1), 63-71, 2016 | 35 | 2016 |
| Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer TMA Abdel-Fatah, C Perry, P Moseley, K Johnson, A Arora, S Chan, ... Breast cancer research and treatment 143, 411-421, 2014 | 33 | 2014 |
| Calpain system protein expression in carcinomas of the pancreas, bile duct and ampulla SJ Storr, AM Zaitoun, A Arora, LG Durrant, DN Lobo, S Madhusudan, ... BMC cancer 12, 1-9, 2012 | 33 | 2012 |
| Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers? TMA Abdel-Fatah, C Perry, A Arora, N Thompson, R Doherty, PM Moseley, ... Antioxidants & redox signaling 21 (16), 2262-2268, 2014 | 32 | 2014 |
| Are DNA repair factors promising biomarkers for personalized therapy in gastric cancer? T Abdel-Fatah, A Arora, I Gorguc, R Abbotts, S Beebeejaun, S Storr, ... Antioxidants & redox signaling 18 (18), 2392-2398, 2013 | 32 | 2013 |
| DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers TMA Abdel-Fatah, A Arora, PM Moseley, C Perry, EA Rakha, AR Green, ... Oncotarget 6 (26), 21964, 2015 | 24 | 2015 |
| Clinicopathological and functional significance of RECQL1 helicase in sporadic breast cancers A Arora, S Parvathaneni, MA Aleskandarany, D Agarwal, R Ali, ... Molecular cancer therapeutics 16 (1), 239-250, 2017 | 17 | 2017 |
